Relapsed Mantle Cell Lymphoma
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB15699 | Brexucabtagene autoleucel | A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ΞΆ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma. |
| DB09053 | Ibrutinib | An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. |
| DB17472 | Pirtobrutinib | A kinase inhibitor used to treat relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB06769 | Bendamustine | 2 | Recruiting | 1 |
| DB00987 | Cytarabine | 2 | Recruiting | 1 |
| DB16222 | Loncastuximab tesirine | 2 | Recruiting | 1 |
| DB00073 | Rituximab | 2 | Recruiting | 1 |
| DB15035 | Zanubrutinib | 2 | Completed | 1 |